Detalhe da pesquisa
1.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
2.
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
J Hematol Oncol
; 10(1): 171, 2017 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29096668